Premium
Serum Receptor Activator of Nuclear Factor‐κ B Ligand, Osteoprotegrin, and Intact Parathyroid Hormone in Hemodialysis and Renal Transplant Patients
Author(s) -
Rashtchizadeh Nadereh,
Ghorbanihaghjo Amir,
Argani Hassan,
Mahmoudi Meimand Saeed,
Safa Javid,
Vatankhahan Hamidreza,
Shahidi Maryam
Publication year - 2012
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/j.1744-9987.2012.01097.x
Subject(s) - medicine , hemodialysis , parathyroid hormone , renal osteodystrophy , endocrinology , dialysis , renal transplant , transplantation , population , gastroenterology , kidney disease , calcium , environmental health
Serum receptor activator of nuclear factor‐κ B ligand and osteoprotegrin are mediated to vascular calcification in the general population. Our knowledge is very sparse in hemodialysis and renal transplant patients. Receptor activator of nuclear factor‐κ B ligand, osteoprotegrin, intact parathyroid hormone, calcium, and phosphorus were measured in blood samples of 45 hemodialysis and 45 age‐matched renal transplant patients. Osteoprotegrin ( P = 0.001) and intact parathyroid hormone ( P = 0.001) levels in the hemodialysis patients were higher than the renal transplant recipients. Osteoprotegrin had positive correlation with duration of dialysis and age in the hemodialysis (r = 0.88, P = 0.001 and r = 0.34, P = 0.02, respectively) and renal transplant patients (r = 0.92, P = 0.001 and r = 0.46, P = 0.001, respectively). Hemodialysis patients have higher osteoprotegrin levels than the renal transplant recipients. It may act as a protective factor for renal osteodystrophy or only as a secondary phenomenon of advanced renal failure.